Third Arc Bio Inc., a clinical stage biotech company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications, today announced the first ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Brodeur, MD, and Stephan A. Grupp, MD, PhD, have been elected to the 2025 class of Fellows of the American Association for Cancer Research (AACR) Academy. Each year, the Fellows of the AACR ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...

The findings, which were recently published in the American Association for Cancer Research (AACR) Journal, reinforce the need to include racially diverse participants in clinical studies.

Good morning, and welcome to Agenus Inc.'s fourth-quarter and year-end 2024 earnings conference call. Currently, all ...

Recently announced positive data from pivotal randomized, placebo-controlled phase 3 clinical trial of CAN-2409 in intermediate-to-high risk, ...

As SU2C’s scientific partner, the American Association for Cancer Research (AACR) and a Scientific Advisory Committee, led by William G. Nelson, M.D., Ph.D., conduct rigorous competitive review ...

GC Cell (KRX:144510), under the leadership of CEO Sungyong Won, announced today the initiation of its domestic Phase 1 clinical trial for GCC2005 (AB‑205), a novel CD5 CAR‑NK cell therapy. This "first ...

Bradley Bernstein, MD, PhD, A. Thomas Look, MD, and William R. Sellers, MD, of Dana-Farber Cancer Institute have been elected as Fellows of the American Association for Cancer Research (AACR) Academy ...